Navigation Links
Angiotech's corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
Date:5/19/2009

drug-eluting stent innovation," said David McFaul, Boston Scientific Senior Vice President, International. "This breakthrough technology combines a new alloy designed for coronary stenting, an innovative stent design and a new delivery system."

The TAXUS Element Stent System is currently being studied in the PERSEUS clinical trial program, which compares the TAXUS Element Stent System to the TAXUS(R) Express(2)(R) Stent System. The program includes the PERSEUS Workhorse and the PERSEUS Small Vessel arms. Both have finished recruiting patients and are estimated to be completed by the end of the year.

While the Element Stent platform represents Boston Scientific's third-generation DES technology, the Company's fourth-generation DES is currently under development. Initial clinical data were presented at the Transcatheter Cardiovascular Therapeutics scientific symposium in 2008; global pivotal trials are expected to begin in 2010. This DES employs the Labcoat technology, which has an ultra thin biodegradable abluminal polymer that delivers a very low dose of paclitaxel to the wall of the treated vessel, and no polymer or drug on the inner surface of the stent. Integrating the Element Stent architecture and a platinum chromium alloy with an optimized drug release, the "Labcoat Element" Stent is designed to deliver a powerful combination of procedural and clinical performance.

In the United States, the TAXUS Element Stent is an investigational device and is limited by applicable law to investigational use only and is not available for sale.

    Forward Looking Statements
    --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the m
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
2. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
3. Vical Names Andrew de Guttadauro Vice President, Corporate Development
4. Signalife Provides Corporate Update
5. Biomira Announces Plan to Reincorporate in the United States
6. Pressure BioSciences, Inc. Provides Corporate Update
7. The 4th Annual BIO Investor Forum to Webcast Alexzas Corporate Presentation
8. Clinsys Clinical Research, Inc. Announces Relocation of Corporate Headquarters
9. ProMed Alliance International Inc. Corporate Name and Trading Symbol Expected to Change Effective Tomorrow
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. New Corporate Website Launched - Focus on Life Scientists, Flow Cytometrists, & Clinicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... Jan. 14, 2014 As pet owners drew up their lists ... them wrote: "Take better care of my furry companion." Nowadays there ... and top-brand carrying cases to take the little canine or feline ... feel compelled to buy some pricey toys at the pet store. ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... Orange, CA (PRWEB) January 14, 2014 Kerr ... a 10-minute video and additional how-to information about dual arch ... Great Restorations with Dual Arch Impressions,” the blog entry serves ... the technique and houses a step-by-step demonstration by Dr. David ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... to Additional Capital Will Enable Revenue Growth, ... Bulletin Board: BLFS), a leading developer and marketer ... tissues, and organs, today announced that it reached ... to increase the Company,s,existing credit facility from $5 ...
... that NanoBio,s nanoemulsion technology is effective when ... used in therapeutic applications and vaccines, ANN ... it will present compelling new data in nine presentations ... programs,in onychomycosis, herpes labialis, cystic fibrosis and an intra-nasal,influenza ...
... NxStage Medical,Inc. (Nasdaq: NXTM ), a ... its Medisystems Division has signed a,long-term product supply ... provider of dialysis services in the United States. ... the Streamline(TM) airless,blood tubing set as well as ...
Cached Biology Technology:BioLife Solutions Credit Facility Increased to $9 Million 2NanoBio to Announce Key Clinical and Preclinical Data in Nine Presentations at ICAAC/IDSA 2008 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 2NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc. 3
(Date:7/9/2014)... pivotal in the development of cancer, viral infection and ... question about one of the most widely-researched proteins in ... of thousands of research papers and millions of pounds ... in Professor Sir Philip Cohen,s laboratory at the University ... is activated. The results are published today ...
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... geographic ranges in which animals can be found, concern ... Does an increased range for a host mean new ... says a team of UC Santa Barbara scientists, including ... published in the Journal of Biogeography , Hechinger, ... opposite may happen: Hosts may actually lose their parasites ...
Breaking Biology News(10 mins):Research reveals how key controller protein is switched on 2No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Not at home on the range 2Not at home on the range 3Not at home on the range 4
... the humble honey bee, researchers at the University of ... understanding the molecular basis of social behavior in humans. ... a model system for social behavior," said Saurabh (pronounced ... affiliate of the university's Institute for Genomic Biology. Using ...
... Children with cancer who suffer hearing loss due to the ... get their hearing back through pharmacological and gene therapy, thanks ... Research Hospital. Mice with a variety of genetic mutations that ... understand age-related hearing loss in adults, as well as hearing ...
... cause of blindness in western society, say experts at The ... eye instrument, they have launched a study to see if ... also explain why the 77-year-old sailor has no need for ... and broccoli are rich in a chemical called lutein, which, ...
Cached Biology News:Honey bee genome holds clues to social behavior 2St. Jude finds clues to hearing loss from chemotherapy 2Why Popeye only has eyes for spinach 2
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Assay Diluent 500 mls...
Mouse monoclonal [4C4] to Y14 ( Abpromise for all tested applications). entrezGeneID: 9939 SwissProtID: Q9Y5S9...
Biology Products: